Main Article Content
Background: Currently, tulle or gentamicin ointment is generally used to prevent wound infections in wound care. Human amniotic membrane has been used in medical fields such as wound care. So far, there is no comparative evidence of the effectiveness of each ingredient. This study aimed to compare the effectiveness of lyophilized amniotic membrane, tulle, and 0.1% gentamicin ointment in the wound healing process. partial thickness on Mus musculus clinically and histologically.
Methods: This type of research is experimental with a post-test-only control group design. There were 24 rats divided into each group. This research was conducted at the anatomical pathology laboratory, Faculty of Medicine, Universitas Andalas, and INA lab in July - September 2023 using rats (Mus musculus), which were divided into 3 treatment groups and one control group.
Results: Clinically, lyophilized amniotic membrane, 0.1% gentamicin ointment, and tulle provided better results than controls regarding erythema variables. Histologically, the results showed that the lyophilized amniotic membrane group had the thinnest epidermis and dermis, as well as better histological scores for granulation, fibroblasts, and collagen than the 0.1% gentamicin ointment, tulle, and control groups. In this study, significant differences in effectiveness were found in terms of erythema, skin thickness, granulation, fibroblast, and collagen histological scores, with better results in the lyophilized amniotic membrane group.
Conclusion: Clinically, lyophilized amniotic membrane, tulle, and 0.1% gentamicin ointment were more effective than controls for wound treatment due to faster reduction in erythema. However, histologically, the lyophilized amniotic membrane was proven to be more effective than tulle, 0.1% gentamicin ointment, and control in terms of epidermis and dermis thickness, granulation level, fibroblasts, and collagen.
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.